AGENDA: DUR BOARD MEETING
Health First Colorado, Colorado Medicaid, Drug Utilization Review Board
Department of Health Care Policy and Financing

Skaggs School of Pharmacy and Pharmaceutical Sciences Building
12850 East Montview Blvd, Aurora CO 80045
Seminar Room- Room 1000; First floor
Parking available in the Henderson/Visitor Parking Garage

February 11th, 2020
5:00 p.m. – 9:00 p.m. Open Session (Note change in starting time!)
DUR BOARD MEMBERS and CO-DUR MEMBERS

<table>
<thead>
<tr>
<th>DUR Board Members</th>
<th>CO-DUR Team</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sheila Botts, PharmD (Chair)</td>
<td>Jeffrey Taylor, PharmD (HCPF)</td>
</tr>
<tr>
<td>Michael Noonan, DO (Vice Chair)</td>
<td>Robert L Page, PharmD, MSPH (CO DUR)</td>
</tr>
<tr>
<td>Scott VanEyk, MD</td>
<td>Brandon Utter, PharmD (CO DUR)</td>
</tr>
<tr>
<td>Allison Blackmer, PharmD</td>
<td>Heather Anderson, PhD (CO DUR)</td>
</tr>
<tr>
<td>Alison Shmerling, MD</td>
<td>Garth Wright, MPH (CO DUR)</td>
</tr>
<tr>
<td>Mary Wilkerson, MD</td>
<td>Gina Moore, PharmD, MBA (CO DUR)</td>
</tr>
<tr>
<td>Liza Wilson Claus, PharmD</td>
<td></td>
</tr>
<tr>
<td>Gosia Thomas, PharmD</td>
<td></td>
</tr>
<tr>
<td>Britt Boehner (Industry Liaison)</td>
<td></td>
</tr>
</tbody>
</table>

Roll Call / Introductions

Approval of Minutes from November 12th, 2019 Meeting

Term expirations for March 31st and Chair/Vice Chair nomination and vote (to be implemented at May 2020 DUR Board Meeting)

Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest:
- Agenda items must be approved in advance, including requests to present information. Please contact the DUR Pharmacist, Jeff Taylor, at jeffrey.taylor@state.co.us with questions.
- Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours before the meeting.

Open Session:

Unfinished Business and General Orders:

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.
www.colorado.gov/hcpf
Updates on Business from Last Meeting:
(items included in this section are not scheduled for public testimony or board review as part of this agenda)

PDL Classes Reviewed:
- Anti-Emetics
- Anti-Platelets
- Antipsoriatrics (Oral and Topical)
- Epinephrine Auto-Injector Products
- Hepatitis C Virus Treatments-Direct-Acting Antivirals
- NSAIDs (Oral and Non-Oral)
- Pulmonary Arterial Hypertension (PAH) Agents
  - Endothelial Antagonists
  - Guanylate Cyclase
  - Phosphodiesterase Inhibitors
  - Prostanoids
- Targeted Immune Modulators(TIMs)
- Non-Biologic Ulcerative Colitis Agents (Oral and Non-Oral)
- Proton Pump Inhibitors
- Mass review drug classes*:
  - Anti-Depressants
    - Monoamine Oxidase Inhibitors (MAOIs)
    - Newer Generation
    - Tricyclics (TCAs)
  - Anti-herpetics (Oral and Topical)
  - Anti-hyperuricemics
  - Fluoroquinolones (Oral)
  - H. Pylori Treatments
  - Hepatitis C –Single-Agent Ribavirin Products
  - Pancreatic Enzymes
  - Triptans and other Migraine Treatments (Oral and Non-Oral)

Other Items Reviewed:
- Criteria for Selected Products Used to Treat Thrombocytopenia:
  - Tavalisse (fostamatinib)
  - Doptelet (avatrombopag)
  - Mulpleta (lusutrombopag)
- Criteria for Selected Inhaled Antibiotic Products:
  - Tobi Podhaler (tobramycin capsule for inhaler)
  - Arikayse (amikacin suspension)
- Criteria for Selected Enzyme Replacement Products:
  - Aldurazyme (laronidase)
Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.

www.colorado.gov/hcpf

- Naglazyme (galsulfase)
- Criteria for Other Selected Products:
  - Glycate (glycopyrollate)
  - Lotemax SM (loteprednol etoabonate ophthalmic gel)
- Review of Products for Drug Label Prior Authorization:
  - Ruzurgi (amifampridine)
  - Firdapse (amifampridine)
  - Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis)

New Business (open for public testimony and board review):

Proposed Criteria for PDL Drug Classes Scheduled for Review:

- Antimigraine Agents – Calcitonin Gene-Related Peptide (CGRP) Inhibitors
- Diabetes Management – Insulins
- Glucagon, Self-Administered
- Multiple Sclerosis Agents
- Immune Globulins
- Anti-Parkinson’s Agents
  - Dopa Decarboxylase Inhibitors & Combinations
  - MAO-Bs
  - Dopamine Agonists
  - Other
- Atypical Antipsychotics
- Lithium Agents
- Ophthalmic Anti-Inflammatories
- Lipotropics
- Sedative Hypnotics
  - Non-Benzodiazepine
  - Benzodiazepine
- Hemorrhoidal and Related Anorectal Agents
- Mass review drug classes*:
  - Bile Salts
  - Growth Hormones
  - Intranasal Rhinitis Agents
  - Leukotriene Modifiers
  - Neurocognitive Disorder Agents
  - Ophthalmic Allergy Agents
  - Ophthalmic Glaucoma Agents
  - Statins & Statin Combinations
  - Topical Steroids
    - Low Potency
    - Medium Potency
    - High Potency
    - Very High Potency
Proposed ProDUR and Prior Authorization Criteria for Other Selected Products:

- Nayzilam (midazolam)
- Dupixent (dupilumab)
- Trikafta (elixacaftor, tezacaftor, and ivacaftor)
- Exondys 51 (eteplirsen injection)
- Vyondys 53 (golodirsen)
- Soliris (eculizumab)
- Ergomar (ergotamine)
- Thiola EC (tiopronin)
- Review of Products for Proposed Drug Label Prior Authorization:
  - Ultomiris (ravulizumab)
  - Revco (elapegademase-lvlr)
  - Lumizyme (alglucosidase alfa)

*Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria previously implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review based on board vote.

Retrospective DUR Activities:

- FDA Updates
- Quarterly Drug Utilization Reports

Adjourn

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at 303-866-3105 or jeffrey.taylor@state.co.us or the 504/ADA Coordinator hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.